SHP has been the topic of several other reports. Liberum Capital reissued a hold rating and issued a GBX 4,900 ($65.95) target price on shares of Shire in a research report on Thursday, August 3rd. Beaufort Securities reissued a long term buy rating and issued a GBX 4,900 ($65.95) target price (down from GBX 6,200 ($83.45)) on shares of Shire in a research report on Friday, August 4th. Deutsche Bank reissued a buy rating and issued a GBX 6,000 ($80.75) target price on shares of Shire in a research report on Friday, August 4th. Credit Suisse Group reissued an outperform rating and issued a GBX 5,350 ($72.01) target price on shares of Shire in a research report on Friday, August 4th. Finally, Berenberg Bank reissued a buy rating and issued a GBX 6,000 ($80.75) target price on shares of Shire in a research report on Wednesday, August 9th. Four equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Shire presently has a consensus rating of Buy and a consensus target price of GBX 5,277.78 ($71.03).
Shares of Shire (LON:SHP) traded down GBX 47 ($0.63) during mid-day trading on Tuesday, hitting GBX 3,564.50 ($47.97). The stock had a trading volume of 2,097,129 shares, compared to its average volume of 2,800,000. Shire has a 1-year low of GBX 3,435.50 ($46.24) and a 1-year high of GBX 5,067 ($68.20).
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/06/j-p-morgan-chase-co-reaffirms-overweight-rating-for-shire-plc-shp.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.